| Abstrakt: |
Researchers from Guangdong Second Provincial General Hospital in China have conducted a study on acute myeloid leukemia (AML) and its prognosis. They focused on ferroptosis, an iron-dependent cell death program, as a potential way to overcome drug resistance in AML. The researchers collected RNA sequencing data and clinical information from AML patients to construct a prognosis prediction model. They identified eight prognosis-related ferroptosis genes (PRFGs) and used them to create a gene signature for predicting AML prognosis. The study found that patients with a low risk score based on the gene signature had significantly increased overall survival compared to those with a high risk score. The researchers also explored the relationship between the gene signature and immune-related pathways, tumor microenvironment, and potential treatment strategies. They concluded that the constructed nomogram incorporating PRFGs could effectively stratify AML patients and predict their prognosis. Additionally, they suggested that combining PARP inhibitors with ferroptosis inducers could be a novel treatment strategy for AML. [Extracted from the article] |
